U.S. Residential REITs Stock News

NYSE:JOE
NYSE:JOEReal Estate

St. Joe (JOE) Could Be 127% Below Fair Value Following Record Second Quarter Results

St. Joe (JOE) just posted its highest second quarter revenue and net income in 20 years, alongside an ongoing dividend and active share repurchases, drawing fresh attention to how the company is allocating capital. See our latest analysis for St. Joe. That backdrop of record second quarter results appears to sit alongside building momentum in St. Joe's stock, with a 12.61% year to date share price return and a 35.34% total shareholder return over the past year at a recent share price of...
NasdaqGS:SYNA
NasdaqGS:SYNASemiconductor

3 AI Stocks Riding The Shift To On Device Models

Artificial intelligence is moving from the data center into your laptop, and Meta’s new open-source Muse models are a clear sign of that shift. When a tech giant talks about spending up to $145b and traders push the stock up 2.1% before the market even opens, investors pay attention. This article looks at 3 AI related stocks exposed to this news and how the same headline can create very different stories for your portfolio. The three AI stocks highlighted below are just a sample, with the...
NYSE:PLOW
NYSE:PLOWMachinery

Douglas Dynamics (PLOW) Raised 2026 Sales Guidance, Has The Upside Already Been Priced In?

Douglas Dynamics (PLOW) has drawn fresh attention after raising its 2026 net sales guidance to a range of US$765 million to US$805 million, following second quarter and six month results released on 3 August 2026. See our latest analysis for Douglas Dynamics. The raised 2026 net sales guidance, solid year to date sales figures and ongoing share repurchases have coincided with firming momentum in Douglas Dynamics’ stock, with a year to date share price return of 34.47% and a 1 year total...
NYSE:GPOR
NYSE:GPOROil and Gas

How Investors Are Reacting To Gulfport Energy (GPOR) Softer Q2 Results And CFO Transition

Gulfport Energy Corporation recently reported past second-quarter 2026 results showing revenue of US$323.23 million and net income of US$87.1 million, alongside slightly lower production volumes and confirmation of full-year production guidance. The company also disclosed the upcoming resignation of Chief Financial Officer Michael Hodges and highlighted continued execution of its large share repurchase program, which together may influence views on leadership stability and capital...
NYSE:MUR
NYSE:MUROil and Gas

Is Murphy Oil (MUR) Rebalancing Too Aggressively Between Growth Projects and Shareholder Payouts?

Murphy Oil Corporation recently reported past second-quarter 2026 results showing revenue of US$928.31 million and net income of US$232.18 million, alongside updated production figures, full-year 2026 guidance, and confirmation of a US$0.35 per-share quarterly dividend. The combination of sharply higher earnings from continuing operations, increased capital spending plans, and ongoing Côte d’Ivoire exploration progress signals meaningful operational momentum and a clearer view of how...
NYSE:FLS
NYSE:FLSMachinery

The Bull Case For Flowserve (FLS) Could Change Following Softer 2026 Sales Outlook And Profit Shift

Flowserve Corporation recently reported second-quarter 2026 results showing slightly lower sales of US$1,169.18 million year on year but higher net income of US$99.00 million, and it trimmed its full-year 2026 total sales growth outlook to approximately 3%. Alongside these updates, Flowserve expanded its board to ten directors and added Carrier executive Ajay Agrawal, signaling an emphasis on services, technology, and risk oversight as the company fine-tunes expectations for the rest of...
NasdaqGS:SRRK
NasdaqGS:SRRKBiotechs

Scholar Rock Holding (SRRK) Advances Apitegromab Review, Is 11% Undervalued Enough?

Scholar Rock Holding (SRRK) has drawn fresh attention after reporting second quarter 2026 results, alongside a detailed update on apitegromab’s regulatory path, including progress with the FDA and EMA and preparations for a possible U.S. launch. See our latest analysis for Scholar Rock Holding. The latest apitegromab update appears to have sharpened focus on Scholar Rock Holding, with the stock’s recent 7 day share price return of 15.42% and year to date share price return of 23.64% sitting...
NYSE:FTV
NYSE:FTVMachinery

How Fortive’s Q2 Beat and Renewed Buybacks At Fortive (FTV) Has Changed Its Investment Story

In late July 2026, Fortive reported second-quarter revenue of US$1,096.8 million with higher earnings per share from continuing operations year-on-year, while also completing a US$200.07 million share repurchase tranche under its multi-year buyback program. Management reiterated a disciplined capital allocation plan centered on organic investment, accretive bolt-on acquisitions, ongoing buybacks, and a modest growing dividend, supported by a revamped M&A engine now in place. Next, we’ll...
NYSE:AHR
NYSE:AHRHealth Care REITs

US REIT Stocks Back In Focus As Lower Yields Lift Healthcare Property Names

Softer US jobs data and easing Treasury yields have quickly shifted attention back to interest rate sensitive areas of the market. That includes US REIT stocks that can feel every move in borrowing costs and inflation expectations. For investors who do not want to wait on the sidelines, this backdrop may create chances to reassess income focused real estate exposure. This article reveals three REIT stocks from the screener that appear positively exposed to the latest macro signals, and...
NasdaqCM:NNE
NasdaqCM:NNEElectrical

Constellation Energy Stock And 2 Nuclear Picks for Reliable Carbon Free Power

Oil price volatility linked to Middle East shipping routes keeps energy security at the center of market conversations. That backdrop puts nuclear energy stocks in sharper focus for investors who want power sources that are not tied to daily oil headlines. The Nuclear Energy Stocks screener filters this broad theme into a focused watchlist. In this article you will see three stand out stocks worth a closer look. The three nuclear energy stocks in this article are just a starting sample, and...
NasdaqGM:SHLS
NasdaqGM:SHLSElectrical

Shoals Technologies Group (SHLS) Reaffirms Guidance As TerraFlow Deal Tests Its Valuation

Shoals Technologies Group (SHLS) has just combined a fresh earnings update with reaffirmed 2026 revenue guidance and a new TerraFlow Energy agreement, giving investors new information on growth, margins and future project visibility. See our latest analysis for Shoals Technologies Group. The recent guidance reaffirmation and TerraFlow Energy MOU come after a mixed share price stretch for Shoals Technologies Group, with a 1-day share price return of 3.84% contrasting with a 30-day share price...
NYSE:LEA
NYSE:LEAAuto Components

Lear (LEA) Raised Full Year Guidance, Is It Still Below Fair Value?

Lear (LEA) drew fresh attention after raising its full-year 2026 revenue guidance to approximately US$23.8b and reporting second-quarter sales of US$6,209.4m with net income of US$192.8m. See our latest analysis for Lear. Lear's recent news around higher full-year revenue guidance and stronger second quarter earnings has come as the share price has been under pressure. The 30 day share price return is down 9.8% and the 90 day share price return is down 9.9%, while the 1 year total shareholder...
NYSE:NHI
NYSE:NHIHealth Care REITs

Is National Health Investors (NHI) Undervalued After Its New COO Appointment?

Why National Health Investors Stock Is Back on Investors’ Radar National Health Investors (NHI) has drawn fresh attention after appointing senior housing veteran Chris Maingot as Chief Operating Officer on July 27, 2026, ahead of its August 11 earnings call. See our latest analysis for National Health Investors. Against this leadership change backdrop, National Health Investors’ share price has been comparatively steady, with a 90 day share price return of 1.17% and a 1 year total shareholder...
NasdaqGS:TDUP
NasdaqGS:TDUPSpecialty Retail

ThredUp (TDUP) Following New Guidance Still Looks Undervalued On Some Views

Why ThredUp Stock Is Back In Focus After New Guidance ThredUp (TDUP) is drawing fresh attention after releasing second quarter 2026 results, alongside new revenue guidance for the next two quarters and the full year, giving investors updated visibility into the resale platform’s growth profile. See our latest analysis for ThredUp. The updated guidance has arrived after a difficult stretch for ThredUp shareholders, with the stock moving to $3.21 and recording a 7-day share price return down...
NYSE:PUMP
NYSE:PUMPEnergy Services

Oil Stocks To Watch As Strait Of Hormuz Disruption Lifts Energy Prices

Energy stocks are back in the spotlight as shipping traffic through the Strait of Hormuz is disrupted, oil prices react, and headlines move markets day by day. When trade routes shift and risk premiums ripple through the system, certain oil and gas producers can see their prospects change quickly. This article walks through 3 stocks from our Energy Sector Stocks screener that appear positively exposed to the current news story. The three stocks covered below are just a starting sample from...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

What Incyte (INCY)'s Expanded Opzelura EU Approval Means For Shareholders

In the past week, Incyte reported that the European Commission approved Opzelura (ruxolitinib) cream for moderate atopic dermatitis in adults who do not respond adequately to or cannot use standard topical therapies, expanding the drug’s European label beyond non-segmental vitiligo. This decision, backed by strong Phase 3 data showing rapid itch relief and durable skin clearance with a favorable safety profile, coincided with Incyte posting higher quarterly revenue and net income and raising...
NYSE:SITE
NYSE:SITETrade Distributors

SiteOne’s Buybacks And Acquisition Push Could Be A Game Changer For SiteOne Landscape Supply (SITE)

In late July 2026, SiteOne Landscape Supply reported second-quarter sales of US$1,530.7 million and net income of US$139.3 million, alongside confirmation that it had repurchased 897,778 shares for US$103.76 million under its ongoing buyback program. Management also highlighted an active acquisition pipeline, with two deals already completed in 2026 adding about US$110 million in trailing sales, signalling continued emphasis on growth through consolidation in a fragmented landscape supply...
NYSE:CBT
NYSE:CBTChemicals

Can Cabot (CBT) Justify Its Valuation Following Weaker Earnings And A CEO Transition?

Cabot (CBT) has drawn investor attention after third quarter earnings on 3 August 2026 showed sharply lower net income and earnings per share, along with previously announced leadership changes at the top of the company. See our latest analysis for Cabot. Cabot's recent earnings miss and upcoming CEO transition sit against a share price that has climbed 30.68% year to date, with a 5 year total shareholder return of 77.28%. This suggests longer term momentum has been stronger than the shorter...
NYSE:CPRI
NYSE:CPRILuxury

Capri Holdings (CPRI) Is Down 6.5% After Raising EPS Guidance Despite Kors Inventory Delays

Capri Holdings Limited recently reported past first-quarter 2027 results, with sales easing to US$769 million while net income rose to US$69 million, and issued new second-quarter and full-year guidance outlining revenue pressures from Michael Kors inventory delays, softer EMEA demand and foreign exchange headwinds. Alongside this, Capri filed a US$41.30 million shelf registration for 2,500,000 common shares tied to an employee share offering, adding a capital structure element to investors’...
NasdaqGS:GH
NasdaqGS:GHHealthcare

Guardant Health (GH) Is Up 6.1% After Raising 2026 Revenue Outlook And Filing Shelf Registration - Has The Bull Case Changed?

In late July 2026, Guardant Health reported second-quarter 2026 results showing sales of US$334.98 million and a net loss of US$120.14 million, alongside higher full-year revenue guidance of US$1.34–1.36 billion. The company also filed an omnibus shelf registration covering multiple securities and highlighted surging Shield screening volumes supported by new UnitedHealth coverage and recent FDA approvals. Next, we’ll examine how Guardant Health’s increased 2026 revenue guidance, underpinned...